Cerebral Medical Leadership and Credentials: What Patients Need to Know

Is Cerebral a Legitimate Medical Provider?

Cerebral holds active medical practice licenses in all 50 states and staffs board-eligible or board-certified prescribers. That baseline satisfies the legal definition of a legitimate provider. The fuller picture is more complicated.

The company grew from roughly 5,000 patients in early 2020 to more than 400,000 by late 2021, a pace that outran its clinical oversight infrastructure according to its own former employees who spoke to The Wall Street Journal in 2022. Rapid growth at that scale strains quality-assurance systems that regulators and professional bodies regard as non-negotiable for safe prescribing. The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 841) and DEA implementing regulations at 21 C.F.R. Part 1306 set explicit requirements for controlled-substance telemedicine, including an in-person evaluation or its documented equivalent before prescribing Schedule II stimulants such as amphetamine salts or methylphenidate.

Licensing Versus Quality

Holding a license and delivering safe care are not the same thing. The Federation of State Medical Boards (FSMB) published a 2022 telemedicine policy statement specifying that the standard of care for remote prescribing "must be equivalent to the standard applied in in-person settings, regardless of modality." Cerebral's own internal documents, reported publicly, suggested that some prescribers were completing evaluations in under 30 minutes for ADHD assessments that national guidelines recommend take 60 to 90 minutes at minimum.

Clinician Workforce Composition

Cerebral employs a mix of physicians (MDs and DOs) and mid-level practitioners (NPs and PAs). The ratio of physicians to mid-levels, and the supervision arrangements for NPs and PAs, vary by state law. In states with full practice authority for NPs, an NP may prescribe Schedule II controlled substances independently. In states requiring physician supervision, Cerebral's supervision ratios and chart-review frequency have not been publicly disclosed in detail, which limits independent verification of oversight quality.

Cerebral's DEA Criminal Referral: What Actually Happened

In May 2022, the DEA referred Cerebral to the U.S. Department of Justice for investigation into potential violations of the Controlled Substances Act related to prescribing of stimulants and benzodiazepines. This is a matter of public record and was first reported by The Wall Street Journal.

The DEA referral is not a conviction and does not by itself constitute proof of wrongdoing. It does, however, represent the most serious regulatory action the agency can take short of revocation of a DEA registration. The underlying concern was that Cerebral allegedly prioritized subscriber growth over clinical rigor in ADHD assessments, potentially resulting in Schedule II prescriptions issued without adequate diagnostic evaluation.

DEA Registration Requirements

Under 21 C.F.R. § 1306.04, a prescription for a controlled substance is valid only if issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. Telemedicine prescribing of Schedule II substances without a prior in-person exam requires DEA special registration, a program that was still in the rulemaking phase during Cerebral's peak growth period in 2021 and 2022. The DEA published its proposed telemedicine special registration rules in February 2023 (88 FR 12875).

Cerebral's Internal Response

Following the referral, Cerebral announced it would stop prescribing Schedule II stimulants (Adderall, Ritalin, Vyvanse) through its platform. That restriction was later partially reversed as regulatory clarity improved. The company also terminated its then-Chief Medical Officer and appointed new clinical leadership with stated commitments to enhanced chart review and prescribing audits.

FDA Safety Communication and Controlled-Substance Prescribing

In March 2023, the FDA issued a Drug Safety Communication noting concerns about telehealth platforms prescribing controlled substances without adequate safeguards. While the FDA did not name Cerebral exclusively, the communication was widely understood in the regulatory community to address the category of rapid-growth ADHD telehealth companies of which Cerebral was the largest.

The FDA's specific concern was the potential for stimulant diversion and for diagnostic assessments that do not meet the standard established by the American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters for ADHD. Those AACAP parameters, last updated with addenda through 2020, require multi-informant assessment, symptom rating scales, and differential diagnosis of comorbid conditions before a stimulant prescription is appropriate.

What the FDA Recommends for Telehealth Prescribing

The FDA's guidance on prescription drug monitoring programs and its 2023 telemedicine prescribing communication both indicate that providers should query state prescription drug monitoring programs (PDMPs) before prescribing Schedule II or III controlled substances. Cerebral's compliance with PDMP queries across all 50 states has not been independently audited and reported in peer-reviewed literature.

LegitScript Certification: Revocation and Its Meaning

LegitScript is a third-party compliance organization whose certification is required by Google, Facebook, and other major advertising platforms for healthcare advertisers. In 2022, LegitScript revoked Cerebral's certification following an investigation into its prescribing practices and marketing claims.

LegitScript's healthcare merchant certification standards require adherence to applicable laws, transparent prescribing protocols, and honest advertising. Revocation means Cerebral cannot legally advertise on Google or Meta under a certified status, though the company may still operate and accept patients through other channels.

Certification is not a federal regulatory requirement and revocation is not a legal finding. It is, however, a commercially significant signal that a major compliance arbiter found Cerebral's practices inconsistent with its standards at that point in time.

State Medical Board Actions and Investigations

At least 10 state medical boards or attorney general offices opened inquiries into Cerebral between 2022 and 2024. States with documented actions include Florida, Texas, New York, California, and Colorado. The specific allegations vary by state but cluster around three themes: inadequate ADHD evaluations, prescribing to patients across state lines by clinicians not licensed in the patient's state, and marketing claims that allegedly overstated diagnostic accuracy.

Florida and Texas Actions

The Florida Department of Health and the Texas Medical Board have published guidance specifically addressing telehealth prescribing of Schedule II stimulants, requiring that evaluations meet the same documentation standards as in-person assessments. Both boards have the authority to sanction individual prescribers employed by Cerebral even if a federal action against the company as an entity is pending or unresolved.

Cross-State Prescribing Compliance

The Interstate Medical Licensure Compact (IMLC) allows eligible physicians to obtain licenses in multiple states more efficiently, but it does not waive state-specific prescribing laws. Cerebral's compliance with IMLC requirements and state-specific telehealth prescribing statutes across its 50-state footprint represents an ongoing administrative complexity that peer-reviewed research on telehealth compliance identifies as a leading source of inadvertent violations. A 2022 analysis in the Journal of Telemedicine and Telecare found that cross-state licensing gaps were the most common regulatory deficiency among large multi-state telehealth platforms.

Consumer Complaints: BBB and CFPB Data

The Better Business Bureau profile for Cerebral (entity: Cerebral Inc.) carried more than 500 complaints as of late 2024, with the most common categories being billing disputes, difficulty canceling subscriptions, and concerns about prescription delays. The BBB assigns Cerebral an accredited rating, which reflects responsiveness to complaints rather than absence of complaints.

The Consumer Financial Protection Bureau (CFPB) received complaints about Cerebral's subscription billing practices, specifically regarding charges that continued after patients believed they had canceled. This is distinct from clinical quality but relevant to the overall trustworthiness assessment because deceptive billing and deceptive prescribing often reflect the same underlying organizational culture.

HealthRX Provider Trust Framework Applied to Cerebral

When evaluating any telehealth platform, HealthRX applies a five-domain framework covering: (1) clinician licensure and board certification rates, (2) regulatory action history, (3) clinical protocol transparency, (4) patient complaint density relative to patient volume, and (5) independent audit or accreditation status.

Applying that framework to Cerebral as of early 2025:

• Clinician licensure: Meets minimum legal requirements; board certification rates for prescribers are not publicly disclosed.
• Regulatory history: Material adverse actions including DEA referral, FDA communication, LegitScript revocation, and multiple state inquiries. No criminal conviction as of publication.
• Protocol transparency: Cerebral publishes general descriptions of its evaluation process but has not published its full clinical protocols for independent review.
• Complaint density: 500+ BBB complaints against a peak patient base of 400,000 represents roughly 0.125% documented complainants, which is within the range seen at other large telehealth platforms but elevated compared to traditional outpatient practices.
• Independent accreditation: No current URAC, NCQA, or Joint Commission telehealth accreditation is listed on Cerebral's website as of January 2025.

Cerebral's Current Medical Leadership

Cerebral has cycled through multiple Chief Medical Officers since its founding. The original CMO departed following the DEA referral. Subsequent medical leadership appointments have emphasized clinical oversight credentials, with recent CMOs holding board certifications in psychiatry from the American Board of Psychiatry and Neurology (ABPN).

Board certification by ABPN requires completion of an accredited residency, passage of written and oral examinations, and ongoing maintenance of certification every 10 years per ABPN standards. Whether the clinical leadership's stated credentials translate into rigorous front-line prescribing oversight depends on the systems and staffing ratios they implement, which have not been externally verified.

Medical Advisory Board

Cerebral lists a medical advisory board on its website. Members listed as of 2024 hold academic affiliations at institutions including Stanford and Johns Hopkins. Academic affiliation alone does not ensure that advisory input shapes day-to-day clinical decisions; the scope and frequency of advisory board engagement with operational prescribing protocols is not disclosed.

Prescriber Supervision Ratios

In states requiring physician supervision of NPs and PAs, the ratio of supervising physicians to supervised practitioners affects the practical ability to review charts and catch prescribing errors. The American Medical Association recommends that supervision ratios not exceed 2:1 to 3:1 in high-acuity settings. Cerebral has not published its supervision ratios, making independent assessment of this parameter impossible from public sources.

ADHD Diagnostic Standards and Cerebral's Protocol Claims

ADHD diagnosis in adults requires meeting DSM-5 criteria: at least five inattentive or hyperactive-impulsive symptoms, symptom onset before age 12, presence in two or more settings, and functional impairment not better explained by another disorder. The DSM-5 criteria are operationalized through validated rating scales such as the Adult ADHD Self-Report Scale (ASRS) and the Conners Adult ADHD Rating Scale (CAARS).

Cerebral's published evaluation workflow states that it uses validated rating scales and clinician interviews. Independent verification of protocol fidelity, meaning whether individual prescribers actually apply these tools consistently, has not been published in peer-reviewed literature specific to Cerebral's patient population.

A 2022 investigation by The Wall Street Journal cited former Cerebral clinicians who reported pressure to complete evaluations quickly and to prescribe when in doubt. Those are firsthand accounts, not controlled research, but they align with the systemic concerns raised by the DEA referral and state investigations.

Comorbidity Screening

Accurate ADHD assessment requires ruling out conditions that mimic inattention and hyperactivity, including anxiety disorders, bipolar disorder, sleep apnea, and thyroid dysfunction. A 2019 systematic review in JAMA Psychiatry found that ADHD is comorbid with at least one other psychiatric condition in approximately 60 to 80% of adults. A telehealth evaluation that does not screen for these comorbidities risks both under-treatment of the comorbid condition and potential harm from stimulant prescribing in contraindicated situations such as active bipolar I disorder.

Cerebral states that its clinicians screen for comorbidities, but the specific screening instruments used and the criteria for deferring stimulant prescribing in the presence of comorbid conditions are not published.

Cerebral vs. Telehealth Industry Standards

For context, the broader telehealth mental health industry has been subject to increasing regulatory scrutiny since 2021. The DEA's proposed telemedicine special registration rule, published in February 2023, would require platforms prescribing Schedule II controlled substances via telehealth to maintain a separate DEA registration and meet enhanced record-keeping requirements. A 2023 JAMA Network Open study examining stimulant prescribing trends found that telehealth-initiated stimulant prescriptions increased by 211% between 2020 and 2022, raising population-level concerns about diagnostic accuracy at scale.

Cerebral was the largest single platform in that prescribing surge. Its regulatory history should therefore be evaluated against an industry that was broadly expanding faster than oversight mechanisms were designed to handle, not against a static pre-pandemic standard.

That context does not excuse specific violations. It does clarify that Cerebral's problems were partly structural to the entire direct-to-consumer ADHD telehealth model, not solely the result of individual bad actors within the company.

Peer Comparison: Cerebral vs. Done, Ahead

Done Global, another ADHD telehealth platform, faced a parallel DEA investigation and ceased operations in 2023 after its DEA registration was suspended. Ahead Health shut down in 2023 as well. Cerebral, by contrast, remains operational. That operational continuity may reflect better compliance outcomes, greater legal resources, or both. It does not by itself resolve the underlying questions about prescribing quality.

What Patients Should Verify Before Using Cerebral

Patients considering Cerebral for psychiatric care or ADHD evaluation should take several concrete steps before committing to a subscription.

First, verify that the specific prescriber assigned to their care is licensed in their state by querying the relevant state medical or nursing board directly. State licensing databases are publicly searchable at no cost. The Federation of State Medical Boards maintains a DocInfo database that allows license and disciplinary history checks for physicians.

Second, ask Cerebral's intake team to specify what assessment instruments will be used for ADHD evaluation and how long the initial evaluation appointment is scheduled to last. A credible ADHD evaluation for an adult should include at minimum the ASRS, a structured clinical interview addressing DSM-5 criteria, and a review of prior records if available. The American Psychiatric Association's Practice Guideline for ADHD specifies these minimum components.

Third, confirm whether the prescriber assigned is an MD, DO, NP, or PA, and in states requiring supervision, ask who the supervising physician is and how often chart reviews occur.

Fourth, read the subscription cancellation terms before entering payment information. The majority of Cerebral's BBB complaints involve billing disputes that patients report finding difficult to resolve after the fact.